Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with Bortezomib and Doxil in Relapsed/Refractory Multiple Myeloma
NCT01492881Phase 2Withdrawn
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Apr 2012
- Primary completion
- Jan 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in multiple myeloma (MM), sponsored by UNC Lineberger Comprehensive Cancer Center. Planned start Apr 2012; status: withdrawn.
02
Drugs
vorinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01492881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01492881.